Global Antidiabetic Glucagon-like Peptide 1 Agonists market growth is projected to reach  US$ 6027 million in 2025 to US$ 7830 million in 2031; it is expected to grow at a CAGR of 4.5% from 2025 to 2031.

Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Trends and Analysis 2025-31

The global Antidiabetic Glucagon-like Peptide 1 Agonists market size is predicted to grow from US$ 6027 million in 2025 to US$ 7830 million in 2031; it is expected to grow at a CAGR of 4.5% from 2025 to 2031. Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia. The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1. Infinity Market Research newest research report, the Antidiabetic Glucagon-like Peptide 1 Agonists Industry Forecast looks at past sales and reviews total world Antidiabetic Glucagon-like Peptide 1 Agonists sales in 2024, providing a comprehensive analysis by region and market sector of projected Antidiabetic Glucagon-like Peptide 1 Agonists sales for 2025 through 2031. With Antidiabetic Glucagon-like Peptide 1 Agonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antidiabetic Glucagon-like Peptide 1 Agonists industry. This Insight Report provides a comprehensive analysis of the global Antidiabetic Glucagon-like Peptide 1 Agonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antidiabetic Glucagon-like Peptide 1 Agonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Antidiabetic Glucagon-like Peptide 1 Agonists market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antidiabetic Glucagon-like Peptide 1 Agonists and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antidiabetic Glucagon-like Peptide 1 Agonists. This report presents a comprehensive overview, market shares, and growth opportunities of Antidiabetic Glucagon-like Peptide 1 Agonists market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Exenatied &nbsp;&nbsp;&nbsp; Liraglutide &nbsp;&nbsp;&nbsp; Lixisenatide &nbsp;&nbsp;&nbsp; Albiglutide &nbsp;&nbsp;&nbsp; Dulaglutide Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Pharmacy This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Novo Nordisk &nbsp;&nbsp;&nbsp; AstraZeneca &nbsp;&nbsp;&nbsp; Eli Lily &nbsp;&nbsp;&nbsp; GSK &nbsp;&nbsp;&nbsp; Sanofi &nbsp;&nbsp;&nbsp; Bristol-Myers Squibb &nbsp;&nbsp;&nbsp; Abbott Laboratories Key Questions Addressed in this Report What is the 10-year outlook for the global Antidiabetic Glucagon-like Peptide 1 Agonists market? What factors are driving Antidiabetic Glucagon-like Peptide 1 Agonists market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Antidiabetic Glucagon-like Peptide 1 Agonists market opportunities vary by end market size? How does Antidiabetic Glucagon-like Peptide 1 Agonists break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Antidiabetic Glucagon-like Peptide 1 Agonists by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Antidiabetic Glucagon-like Peptide 1 Agonists by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Antidiabetic Glucagon-like Peptide 1 Agonists Segment by Type &nbsp;2.2.1 Exenatied &nbsp;2.2.2 Liraglutide &nbsp;2.2.3 Lixisenatide &nbsp;2.2.4 Albiglutide &nbsp;2.2.5 Dulaglutide &nbsp;2.3 Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type &nbsp;2.3.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sale Price by Type (2020-2025) &nbsp;2.4 Antidiabetic Glucagon-like Peptide 1 Agonists Segment by Application &nbsp;2.4.1 Hospital &nbsp;2.4.2 Pharmacy &nbsp;2.5 Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application &nbsp;2.5.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Breakdown Data by Company &nbsp;3.1.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Company (2020-2025) &nbsp;3.2.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sale Price by Company &nbsp;3.4 Key Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Product Location Distribution &nbsp;3.4.2 Players Antidiabetic Glucagon-like Peptide 1 Agonists Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Antidiabetic Glucagon-like Peptide 1 Agonists by Geographic Region &nbsp;4.1 World Historic Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Antidiabetic Glucagon-like Peptide 1 Agonists Sales Growth &nbsp;4.4 APAC Antidiabetic Glucagon-like Peptide 1 Agonists Sales Growth &nbsp;4.5 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Growth &nbsp;4.6 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Growth 5 Americas &nbsp;5.1 Americas Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country &nbsp;5.1.1 Americas Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2020-2025) &nbsp;5.1.2 Americas Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2020-2025) &nbsp;5.2 Americas Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2020-2025) &nbsp;5.3 Americas Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region &nbsp;6.1.1 APAC Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2020-2025) &nbsp;6.1.2 APAC Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Region (2020-2025) &nbsp;6.2 APAC Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2020-2025) &nbsp;6.3 APAC Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists by Country &nbsp;7.1.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2020-2025) &nbsp;7.1.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2020-2025) &nbsp;7.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2020-2025) &nbsp;7.3 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists by Country &nbsp;8.1.1 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Antidiabetic Glucagon-like Peptide 1 Agonists &nbsp;10.3 Manufacturing Process Analysis of Antidiabetic Glucagon-like Peptide 1 Agonists &nbsp;10.4 Industry Chain Structure of Antidiabetic Glucagon-like Peptide 1 Agonists 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Antidiabetic Glucagon-like Peptide 1 Agonists Distributors &nbsp;11.3 Antidiabetic Glucagon-like Peptide 1 Agonists Customer 12 World Forecast Review for Antidiabetic Glucagon-like Peptide 1 Agonists by Geographic Region &nbsp;12.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Forecast by Region &nbsp;12.1.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Forecast by Region (2026-2031) &nbsp;12.1.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Antidiabetic Glucagon-like Peptide 1 Agonists Forecast by Type (2026-2031) &nbsp;12.7 Global Antidiabetic Glucagon-like Peptide 1 Agonists Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Novo Nordisk &nbsp;13.1.1 Novo Nordisk Company Information &nbsp;13.1.2 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolios and Specifications &nbsp;13.1.3 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Novo Nordisk Main Business Overview &nbsp;13.1.5 Novo Nordisk Latest Developments &nbsp;13.2 AstraZeneca &nbsp;13.2.1 AstraZeneca Company Information &nbsp;13.2.2 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolios and Specifications &nbsp;13.2.3 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 AstraZeneca Main Business Overview &nbsp;13.2.5 AstraZeneca Latest Developments &nbsp;13.3 Eli Lily &nbsp;13.3.1 Eli Lily Company Information &nbsp;13.3.2 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolios and Specifications &nbsp;13.3.3 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Eli Lily Main Business Overview &nbsp;13.3.5 Eli Lily Latest Developments &nbsp;13.4 GSK &nbsp;13.4.1 GSK Company Information &nbsp;13.4.2 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolios and Specifications &nbsp;13.4.3 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 GSK Main Business Overview &nbsp;13.4.5 GSK Latest Developments &nbsp;13.5 Sanofi &nbsp;13.5.1 Sanofi Company Information &nbsp;13.5.2 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolios and Specifications &nbsp;13.5.3 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Sanofi Main Business Overview &nbsp;13.5.5 Sanofi Latest Developments &nbsp;13.6 Bristol-Myers Squibb &nbsp;13.6.1 Bristol-Myers Squibb Company Information &nbsp;13.6.2 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolios and Specifications &nbsp;13.6.3 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Bristol-Myers Squibb Main Business Overview &nbsp;13.6.5 Bristol-Myers Squibb Latest Developments &nbsp;13.7 Abbott Laboratories &nbsp;13.7.1 Abbott Laboratories Company Information &nbsp;13.7.2 Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Product Portfolios and Specifications &nbsp;13.7.3 Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Abbott Laboratories Main Business Overview &nbsp;13.7.5 Abbott Laboratories Latest Developments 14 Research Findings and Conclusion

Report	Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Growth 2025-2031
Selected License	Single ID:LPI13660

Buyer Information

Order Summary